| Primary |
| Rheumatoid Arthritis |
38.1% |
| Acute Lymphocytic Leukaemia |
19.2% |
| Bone Sarcoma |
5.1% |
| Product Used For Unknown Indication |
4.9% |
| Psoriasis |
4.4% |
| Psoriatic Arthropathy |
3.7% |
| Non-hodgkin's Lymphoma |
2.9% |
| Prophylaxis Against Graft Versus Host Disease |
2.5% |
| B Precursor Type Acute Leukaemia |
2.2% |
| Acute Promyelocytic Leukaemia |
2.1% |
| Breast Cancer |
2.0% |
| Central Nervous System Lymphoma |
1.9% |
| Drug Use For Unknown Indication |
1.8% |
| Juvenile Arthritis |
1.8% |
| Arthritis |
1.5% |
| Burkitt's Lymphoma |
1.5% |
| Acute Myeloid Leukaemia |
1.2% |
| Crohn's Disease |
1.2% |
| Chemotherapy |
1.1% |
| Prophylaxis |
1.1% |
|
| Vomiting |
12.7% |
| Sepsis |
7.7% |
| Neurotoxicity |
6.8% |
| Stomatitis |
6.6% |
| Toxicity To Various Agents |
5.6% |
| Pancytopenia |
5.6% |
| Thrombocytopenia |
5.6% |
| Renal Failure Acute |
5.4% |
| Weight Decreased |
5.1% |
| Renal Failure |
4.9% |
| Pyrexia |
4.8% |
| Pneumonia |
4.2% |
| Medication Error |
4.0% |
| Drug Ineffective |
3.8% |
| White Blood Cell Count Decreased |
3.6% |
| Respiratory Failure |
2.9% |
| Septic Shock |
2.8% |
| Lymphoproliferative Disorder |
2.7% |
| Breast Cancer |
2.6% |
| Glioma |
2.6% |
|
| Secondary |
| Rheumatoid Arthritis |
36.0% |
| Acute Lymphocytic Leukaemia |
17.4% |
| Product Used For Unknown Indication |
10.3% |
| Drug Use For Unknown Indication |
6.6% |
| Prophylaxis |
4.7% |
| Burkitt's Lymphoma |
4.2% |
| Diffuse Large B-cell Lymphoma |
2.4% |
| Psoriatic Arthropathy |
2.0% |
| Non-hodgkin's Lymphoma |
1.9% |
| Hypertension |
1.7% |
| Prophylaxis Against Graft Versus Host Disease |
1.6% |
| Breast Cancer |
1.5% |
| Mantle Cell Lymphoma |
1.5% |
| Psoriasis |
1.4% |
| Chromosome Analysis Abnormal |
1.3% |
| Lymphoma |
1.2% |
| Crohn's Disease |
1.2% |
| Osteoporosis |
1.1% |
| Burkitt's Leukaemia |
1.1% |
| B Precursor Type Acute Leukaemia |
1.1% |
|
| Sepsis |
11.5% |
| Vomiting |
9.5% |
| Pneumonia |
9.2% |
| Pyrexia |
6.5% |
| Pneumocystis Jiroveci Pneumonia |
5.9% |
| White Blood Cell Count Decreased |
5.4% |
| Thrombocytopenia |
5.0% |
| Off Label Use |
4.5% |
| Lung Neoplasm |
4.3% |
| Weight Decreased |
4.2% |
| Lymphoma |
3.9% |
| Interstitial Lung Disease |
3.9% |
| Septic Shock |
3.7% |
| Neutropenia |
3.5% |
| Rheumatoid Arthritis |
3.4% |
| Respiratory Failure |
3.4% |
| Stomatitis |
3.3% |
| Urinary Tract Infection |
3.0% |
| Death |
2.9% |
| Pulmonary Embolism |
2.9% |
|
| Concomitant |
| Rheumatoid Arthritis |
37.7% |
| Product Used For Unknown Indication |
21.1% |
| Drug Use For Unknown Indication |
12.5% |
| Psoriatic Arthropathy |
3.9% |
| Hypertension |
3.0% |
| Prophylaxis |
2.6% |
| Pain |
2.1% |
| Psoriasis |
2.1% |
| Prophylaxis Against Graft Versus Host Disease |
2.0% |
| Crohn's Disease |
1.9% |
| Vitamin Supplementation |
1.6% |
| Osteoporosis |
1.5% |
| Ankylosing Spondylitis |
1.1% |
| Infection Prophylaxis |
1.1% |
| Arthritis |
1.0% |
| Depression |
1.0% |
| Bone Marrow Conditioning Regimen |
1.0% |
| Juvenile Arthritis |
0.9% |
| Diabetes Mellitus |
0.9% |
| Premedication |
0.8% |
|
| Injection Site Pain |
17.0% |
| Rheumatoid Arthritis |
11.1% |
| Vomiting |
6.7% |
| Drug Ineffective |
5.8% |
| Pain In Extremity |
5.0% |
| Sinusitis |
4.7% |
| Pain |
4.6% |
| Pyrexia |
4.6% |
| Pneumonia |
4.4% |
| Weight Decreased |
4.2% |
| Urinary Tract Infection |
3.9% |
| Injection Site Swelling |
3.9% |
| Nasopharyngitis |
3.3% |
| Weight Increased |
3.3% |
| Nausea |
3.2% |
| Injection Site Reaction |
3.2% |
| Rash |
2.9% |
| Psoriasis |
2.9% |
| Sepsis |
2.7% |
| Headache |
2.6% |
|
| Interacting |
| Rheumatoid Arthritis |
22.6% |
| Product Used For Unknown Indication |
14.7% |
| Breast Cancer |
9.2% |
| Drug Use For Unknown Indication |
7.3% |
| Osteoporosis |
6.6% |
| Non-hodgkin's Lymphoma |
4.7% |
| Infection |
4.6% |
| Acute Lymphocytic Leukaemia |
4.2% |
| Hypertension |
2.9% |
| Nasopharyngitis |
2.8% |
| Antifungal Prophylaxis |
2.6% |
| Metastasis |
2.5% |
| Psoriatic Arthropathy |
2.4% |
| Psoriasis |
2.2% |
| Bone Sarcoma |
1.9% |
| Ill-defined Disorder |
1.9% |
| Spindle Cell Sarcoma |
1.9% |
| Acute Myeloid Leukaemia |
1.8% |
| Gastritis |
1.6% |
| Precursor T-lymphoblastic Lymphoma/leukaemia |
1.5% |
|
| Renal Failure Acute |
14.3% |
| Drug Interaction |
12.8% |
| Vomiting |
10.7% |
| Photosensitivity Reaction |
8.2% |
| Osteonecrosis |
4.6% |
| Rhinorrhoea |
4.6% |
| Mucosal Inflammation |
4.1% |
| Neutropenia |
4.1% |
| Pancytopenia |
4.1% |
| White Blood Cell Count Decreased |
4.1% |
| Haemoglobin Decreased |
3.6% |
| Renal Failure |
3.6% |
| Sepsis |
3.6% |
| Rash Macular |
3.1% |
| Weight Decreased |
3.1% |
| Pneumonia Legionella |
2.6% |
| Pneumonitis |
2.6% |
| Toxicity To Various Agents |
2.6% |
| Acute Prerenal Failure |
2.0% |
| Blood Creatinine Increased |
2.0% |
|
